David Y. Oh

David Y. Oh is an American spacecraft systems engineer and expert in electric propulsion. Dr. Oh currently works at the Jet Propulsion Laboratory (JPL) as the NASA Psyche mission chief engineer. Prior to this role he served as the Project Systems Engineering Manager for Psyche. He was also the cross-cutting phase lead and lead flight director for the NASA Mars Science Laboratory mission (Curiosity Mars rover) and was recognized in popular media for living on Mars time with his family during the month following the landing of the Curiosity rover. Provided by Wikipedia
Showing 1 - 4 results of 4 for search 'David Y. Oh', query time: 0.03s Refine Results
  1. 1
    862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients

    862 TLR9 agonism promotes cytotoxic T cell persistence and myeloid remodeling when combined with radiation therapy and PD-1 blockade in oligometastatic prostate cancer patients by Li Zhang, Lawrence Fong, David Y Oh, Eliezer Van Allen, Felix Y Feng, Anthony Wong, Eric J Small, Terence W Friedlander, Alec Starzinski, Zenghua Fan, Tony Li, Hewitt Chang, Marissa Gin, Katsuto Shinohara, Hao Nguyen, Caleb Hwang, Christopher De Leon, Rahul R Aggarwal

    Published 2023-11-01
    Article
  2. 2
    Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis

    Dysregulation of CD4+ and CD8+ resident memory T, myeloid, and stromal cells in steroid-experienced, checkpoint inhibitor colitis by Li Zhang, Lawrence Fong, Brittany Davidson, David Y Oh, Frances Fan, Alexander Cheung, Hai Yang, Jun Yan He, Yang-Joon Kim, Elvira Mennillo, Iulia Rusu, Jared Bain, Arjun A Rao, Christopher Andersen, Karen Law, Jessica Tsui, Alan Shen, Divyashree Kushnoor, Yimin Shi, Alexis J Combes, Angela O Pisco, Michael G Kattah

    Published 2024-04-01
    Get full text
    Article
  3. 3
    TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

    TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor by Li Zhang, Divya Natesan, Lawrence Fong, Emily Chan, David Y Oh, Son Ho, Ivan de Kouchkovsky, Errol J Philip, Francis Wright, Daniel M Kim, Daniel Kwon, Hansen Ho, Sima P Porten, Anthony C Wong, Arpita Desai, Franklin W Huang, Jonathan Chou, Raj S Pruthi, Eric J Small, Terence W Friedlander, Vadim S Koshkin

    Published 2021-05-01
    Get full text
    Article
  4. 4
    Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis

    Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis by Elvira Mennillo, Yang Joon Kim, Gyehyun Lee, Iulia Rusu, Ravi K. Patel, Leah C. Dorman, Emily Flynn, Stephanie Li, Jared L. Bain, Christopher Andersen, Arjun Rao, Stanley Tamaki, Jessica Tsui, Alan Shen, Madison L. Lotstein, Maha Rahim, Mohammad Naser, Faviola Bernard-Vazquez, Walter Eckalbar, Soo-jin Cho, Kendall Beck, Najwa El-Nachef, Sara Lewin, Daniel R. Selvig, Jonathan P. Terdiman, Uma Mahadevan, David Y. Oh, Gabriela K. Fragiadakis, Angela Pisco, Alexis J. Combes, Michael G. Kattah

    Published 2024-02-01
    Get full text
    Article

Search Tools: